International journal of molecular sciencesJun 26, 2026

Semaglutide improves metabolism and thinking ability in a mouse model of Alzheimer’s disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Jun 27, 2026

Abstract

SMGL treatment for 13 weeks in metabolically challenged 5xFAD HFD mice resulted in reduced body weight and improved glucose tolerance.

Treatment with SMGL led to normalized cholesterol levels and a restored balance of adiponectin and leptin in 5xFAD HFD mice.
Significant reductions in Aβ40 and Aβ42 levels were observed, indicating a potential impact on Alzheimer’s disease pathology.
Increased levels of synaptophysin and βIII-tubulin were noted, which are associated with enhanced synaptic function.
Immunoreactivity markers for inflammation decreased in the hippocampus and cortex, suggesting anti-inflammatory effects of SMGL.
Minimal metabolic responses were observed in WT RD mice, implying that excessive GLP-1 receptor activation may negatively affect neuronal health under normal metabolic conditions.

Simplified

Alzheimer's disease (AD) and metabolic syndrome often occur together, sharing characteristics such as insulin resistance, dyslipidemia, and chronic inflammation. Metabolic dysfunction frequently precedes cognitive decline, indicating that early intervention might alter the disease's progression. We investigated whether the GLP-1 receptor agonist semaglutide (SMGL) influences metabolic impairment and AD pathology in an AD mouse model. Male and female 5xFAD and wild-type (WT) mice on regular (RD) or high-fat diets (HFD) were administered SMGL for 13 weeks. SMGL-treated groups exhibited significant, context-dependent effects. In metabolically challenged 5xFAD HFD mice, treatment led to reduced body weight, improved glucose tolerance, normalized cholesterol levels, and a restored balance of adiponectin and leptin. These improvements were associated with reduced Aβ40 and Aβ42 levels, restored GLP-1 receptor expression, increased synaptophysin and βIII-tubulin levels, and enhanced spatial memory. SMGL also decreased Iba1 and CD68 immunoreactivity in the hippocampus and cortex, reduced macrophage infiltration, and lowered CD36 expression in visceral adipose tissue (VAT), indicating coordinated anti-inflammatory effects. WT RD mice showed minimal metabolic responses and a modest decline in Y-maze performance, suggesting that excessive GLP-1 receptor activation may disrupt neuronal homeostasis when metabolic status is normal. SMGL acts as a context-specific metabolic and neuroprotective agent, offering the greatest benefits under conditions of metabolic dysfunction. These findings in a preclinical model suggest that targeting early metabolic disturbances provides a testable hypothesis for attenuating AD-related neurodegeneration, though further translational studies are required.

Funding

Competing interests

The authors declare no conflicts of interest.

PubMed

Semaglutide improves metabolism and thinking ability in a mouse model of Alzheimer’s disease

Abstract

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief